Arkansas Blue Cross Blue ShieldCommercial · Administrative · Medical Policy · AR · Neurology, Oncology, HematologyLow impact
Policy Criteria Changes
Act
by Nov 15, 2025
Effective date
Nov 15, 2025
Identified
Jun 19, 2026
Summary
Arkansas Blue Cross is reorganizing spinal muscular atrophy treatment policies by splitting one policy into three separate policies for different drugs, and adding new safety guidelines for Ublituximab and Caplacizumab treatments. All changes are administrative reorganizations with no impact on coverage or billing requirements.
Get alerts when payers change rules like this one
We check Arkansas Blue Cross Blue Shield and other payers every day and email you when a change matches your specialty and state.
01Update prior authorization reference materials to use new policy numbers - Policy 2025026 for Zolgensma and Policy 2025027 for Evrysdi instead of the old combined Policy 2019011.
02Inform providers that prescribing Briumvi requires ensuring no active serious infections including Hepatitis B, and Cablivi requires monitoring for severe infusion reactions or hemorrhage.
Original notice
Policy Criteria Changes
assets.contentstack.io no longer serves this document. We saved a copy on Nov 7, 2026.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.